Insulin Pumps Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Insulin Pumps Pipeline Market Report Overview

An insulin pump is an insulin delivery device that administers programmed doses of insulin for diabetes management. The device consists of a battery run pump, an insulin reservoir and an infusion set with a tubing system for subcutaneous intervention. Traditional Insulin Pumps & Accessories and patch pumps are tracked under this segment.

The insulin pumps pipeline market research report provides comprehensive information about the Insulin pumps pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Key Segments ·       Patch Pumps

·       Programmable Insulin Patch Pumps

·       Disposable Insulin Pumps

·       Programmable Insulin Patch Pumps – Pods

·       Traditional Infusion Sets

Key Territories ·       The US

·       Europe

·       China

·       Canada

·       Others

Key Regulatory Paths ·       510(k)

·       CE

·       NMPA

·       MDL

·       Others

Leading Companies ·       AMF Medical SA

·       Embecta Corp

·       Hospira Inc

·       LifeScan Inc

·       Others

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Insulin Pumps Pipeline Market by Segments

The key segments in the insulin pumps market are patch pumps, programmable insulin patch pumps, disposable insulin pumps, programmable insulin patch pumps – pods, and traditional infusion sets among others. As of July 2023, the patch pumps had the highest number of pipeline products. They include Programmable Insulin Patch Pumps and Non-Programmable Insulin Patch Pumps.

Insulin Pumps Pipeline Market Analysis by Segments, 2023 (%)

Insulin Pumps Pipeline Market Analysis by Segments, 2023 (%)

For more segment insights into the Insulin pumps pipeline market, download a free report sample

Insulin Pumps Pipeline Market Segmentation by Territories

Some of the key territories in the insulin pumps market are the US, Europe, China, Canada, India, and Israel among others. As of July 2023, the US had the highest number of pipeline products.

Insulin Pumps Pipeline Market Analysis by Territories, 2023 (%)

Insulin Pumps Pipeline Market Analysis by Territories, 2023 (%)

For more territory insights into the Insulin pumps pipeline market, download a free report sample

Insulin Pumps Pipeline Market Segmentation by Regulatory Paths

Some of the key regulatory paths in the insulin pump pipeline market are 510(k), CE, NMPA, MDL, ICAC, and PMA among others. As of July 2023, 510(k) was the most followed pathway for pipeline products.

Insulin Pumps Pipeline Market Analysis by Regulatory Paths, 2023 (%)

Insulin Pumps Pipeline Market Analysis by Regulatory Paths, 2023 (%)

For more regulatory path insights into the insulin pumps pipeline market, download a free report sample

Insulin Pumps Pipeline Market – Competitive Landscape

Some of the key companies in the insulin pumps pipeline market are AMF Medical SA, Embecta Corp, Hospira Inc, Insulet Corp, LifeScan Inc, and Medtronic Plc among others.

AMF Medical SA: AMF Medical SA (AMF Medical) develops novel technology to address the unmet needs of people on insulin therapy. AMF Medical is headquartered in Ecublens, Switzerland.

Embecta Corp: Embecta Corp is a healthcare and medical equipment supplier. It offers pharma, health monitoring, and other related products. The company is headquartered in Franklin Lakes, New Jersey, the US.

Leading Insulin Pumps Companies, 2023

Leading Insulin Pumps Companies, 2023

For more company insights into the insulin pumps pipeline market, download a free report sample

Segments Covered in the Report

Insulin Pumps Pipeline Market Segments Outlook

  • Patch Pumps
  • Programmable Insulin Patch Pumps
  • Disposable Insulin Pumps
  • Programmable Insulin Patch Pumps – Pods
  • Traditional Infusion Sets

Insulin Pumps Pipeline Market Territories Outlook

  • The US
  • Europe
  • China
  • Canada
  • Others

Insulin Pumps Pipeline Market Regulatory Paths Outlook

  • 510(k)
  • CE
  • NMPA
  • MDL
  • Others

Scope

This report provides:

  • Extensive coverage of the insulin pumps under development.
  • Details of major pipeline products which includes product description, licensing and collaboration details, and other developmental activities.
  • Reviews of the major players involved in the development of Insulin pumps and lists of all their pipeline projects.
  • Coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage.
  • Key clinical trial data of ongoing trials specific to pipeline products.
  • Recent developments in the segment/industry.

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.
  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.
  • Identify and understand important and diverse types of Insulin pumps under development.
  • Develop market-entry and market-expansion strategies.
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.
  • In-depth analysis of the product’s current stage of development, territory, and estimated launch date

AMF Medical SA
Amrita Vishwa Vidyapeetham
Andain, Inc
Cellnovo Ltd (Inactive)
Debiotech SA
Embecta Corp
Hospira Inc
Insulet Corp
Kailian Medical Technology Co Ltd
LifeScan Inc
MedSolve Technologies, Inc.
Medtronic MiniMed Inc
Medtronic Plc
MicroPort Scientific Corp
MicroTech Medical Co Ltd
Modular Medical Inc
Pennsylvania State University
Phluid Corporation
PhysioLogic Devices Inc
Qlibrium Inc
SFC Fluidics LLC
Sooil Development Co., Ltd.
Spring Health Solutions Ltd.
Tandem Diabetes Care Inc
Thermalin Inc
Triple Jump Israel Ltd
University of Limerick
Univlabs Technologies Pvt Ltd
Unomedical a/s
ViCentra BV
Ypsomed Holding AG

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 6

|1.2 List of Figures 10

2 Introduction 11

2.1 Insulin Pumps Overview 11

3 Products under Development 12

3.1 Insulin Pumps – Pipeline Products by Stage of Development 12

3.2 Insulin Pumps – Pipeline Products by Segment 13

3.3 Insulin Pumps – Pipeline Products by Territory 14

3.4 Insulin Pumps – Pipeline Products by Regulatory Path 15

3.5 Insulin Pumps – Pipeline Products by Estimated Approval Date 16

3.6 Insulin Pumps – Ongoing Clinical Trials 17

4 Insulin Pumps – Pipeline Products under Development by Companies 18

4.1 Insulin Pumps Companies – Pipeline Products by Stage of Development 18

4.2 Insulin Pumps – Pipeline Products by Stage of Development 20

5 Insulin Pumps Companies and Product Overview 22

5.1 AMF Medical SA Company Overview 22

5.1.1 AMF Medical SA Pipeline Products & Ongoing Clinical Trials Overview 22

5.2 Amrita Vishwa Vidyapeetham Company Overview 23

5.2.1 Amrita Vishwa Vidyapeetham Pipeline Products & Ongoing Clinical Trials Overview 23

5.3 Andain, Inc Company Overview 24

5.3.1 Andain, Inc Pipeline Products & Ongoing Clinical Trials Overview 24

5.4 Cellnovo Ltd (Inactive) Company Overview 26

5.4.1 Cellnovo Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 26

5.5 Debiotech SA Company Overview 27

5.5.1 Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 27

5.6 Embecta Corp Company Overview 29

5.6.1 Embecta Corp Pipeline Products & Ongoing Clinical Trials Overview 29

5.7 Hospira Inc Company Overview 30

5.7.1 Hospira Inc Pipeline Products & Ongoing Clinical Trials Overview 30

5.8 Insulet Corp Company Overview 31

5.8.1 Insulet Corp Pipeline Products & Ongoing Clinical Trials Overview 31

5.9 Kailian Medical Technology Co Ltd Company Overview 38

5.9.1 Kailian Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 38

5.10 LifeScan Inc Company Overview 40

5.10.1 LifeScan Inc Pipeline Products & Ongoing Clinical Trials Overview 40

5.11 MedSolve Technologies, Inc. Company Overview 41

5.11.1 MedSolve Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 41

5.12 Medtronic MiniMed Inc Company Overview 42

5.12.1 Medtronic MiniMed Inc Pipeline Products & Ongoing Clinical Trials Overview 42

5.13 Medtronic Plc Company Overview 51

5.13.1 Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview 51

5.14 MicroPort Scientific Corp Company Overview 53

5.14.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 53

5.15 MicroTech Medical Co Ltd Company Overview 55

5.15.1 MicroTech Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 55

5.16 Modular Medical Inc Company Overview 57

5.16.1 Modular Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 57

5.17 Pennsylvania State University Company Overview 59

5.17.1 Pennsylvania State University Pipeline Products & Ongoing Clinical Trials Overview 59

5.18 Phluid Corporation Company Overview 60

5.18.1 Phluid Corporation Pipeline Products & Ongoing Clinical Trials Overview 60

5.19 PhysioLogic Devices Inc Company Overview 61

5.19.1 PhysioLogic Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 61

5.20 Qlibrium Inc Company Overview 62

5.20.1 Qlibrium Inc Pipeline Products & Ongoing Clinical Trials Overview 62

5.21 SFC Fluidics LLC Company Overview 63

5.21.1 SFC Fluidics LLC Pipeline Products & Ongoing Clinical Trials Overview 63

5.22 Sooil Development Co., Ltd. Company Overview 66

5.22.1 Sooil Development Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 66

5.23 Spring Health Solutions Ltd. Company Overview 67

5.23.1 Spring Health Solutions Ltd. Pipeline Products & Ongoing Clinical Trials Overview 67

5.24 Tandem Diabetes Care Inc Company Overview 68

5.24.1 Tandem Diabetes Care Inc Pipeline Products & Ongoing Clinical Trials Overview 68

5.25 Thermalin Inc Company Overview 74

5.25.1 Thermalin Inc Pipeline Products & Ongoing Clinical Trials Overview 74

5.26 Triple Jump Israel Ltd Company Overview 77

5.26.1 Triple Jump Israel Ltd Pipeline Products & Ongoing Clinical Trials Overview 77

5.27 University of Limerick Company Overview 78

5.27.1 University of Limerick Pipeline Products & Ongoing Clinical Trials Overview 78

5.28 Univlabs Technologies Pvt Ltd Company Overview 79

5.28.1 Univlabs Technologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 79

5.29 Unomedical a/s Company Overview 80

5.29.1 Unomedical a/s Pipeline Products & Ongoing Clinical Trials Overview 80

5.30 ViCentra BV Company Overview 81

5.30.1 ViCentra BV Pipeline Products & Ongoing Clinical Trials Overview 81

5.31 Ypsomed Holding AG Company Overview 82

5.31.1 Ypsomed Holding AG Pipeline Products & Ongoing Clinical Trials Overview 82

6 Insulin Pumps- Recent Developments 88

6.1 Jul 11, 2023: Microport Scientific Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023 88

6.2 Jul 05, 2023: Insulet to Announce Second Quarter 2023 Financial Results on August 8, 2023 88

6.3 Jun 12, 2023: Medtronic to present new data on its intelligent dosing platforms at the American Diabetes Association 83rd Scientific Sessions 88

6.4 Jun 12, 2023: Abbott Names Philip Boudreau CFO effective Sept. 1 90

6.5 May 18, 2023: Microtech Medical Announces Poll Results of the Annual General Meeting of 2022 and Appointment of Auditors 91

6.6 May 11, 2023: Medtronic to announce financial results for its fourth quarter and full fiscal year 2023 92

6.7 Apr 27, 2023: Integer Holdings reports First Quarter 2023 results 92

6.8 Apr 26, 2023: MicroPort announces annual results for 2022 94

6.9 Apr 13, 2023: Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results 94

6.10 Apr 12, 2023: Medtronic has a layoff in California 94

6.11 Mar 30, 2023: Integer Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023 95

6.12 Mar 22, 2023: ConvaTec Group Notice of Annual General Meeting 95

6.13 Mar 16, 2023: Medtronic joins in $25M funding round for home monitoring company 96

6.14 Mar 09, 2023: ConvaTec Group Announces Annual Results for the twelve months ended 31 December 2022 96

6.15 Feb 24, 2023: Insulet Reports Full Year 2022 Revenue Increase of 19% and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year 98

6.16 Feb 16, 2023: Integer Holdings Reports Results for Fourth Quarter and Full Year 2022 101

6.17 Feb 02, 2023: F. Hoffmann-La Roche Announces Financial Results for fiscal 2022 104

6.18 Jan 19, 2023: Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results 104

6.19 Jan 19, 2023: Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023 104

6.20 Jan 12, 2023: Insulet to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 104

6.21 Dec 13, 2022: Thomas Schinecker replaces Severin Schwan as Roche’s new CEO 104

6.22 Nov 29, 2022: Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement 105

6.23 Nov 23, 2022: Medtronic Reports Quarterly Earnings 105

6.24 Nov 22, 2022: Medtronic reports second quarter fiscal 2023 financial results 105

6.25 Nov 15, 2022: Medtronic Set to Announce Earnings on Tuesday 111

6.26 Nov 14, 2022: EOFlow Reports Third Quarter 2022 Revenue of

3.5 Billion KRW…Increase of 916% Year-Over-Year 111

6.27 Nov 01, 2022: Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress 111

6.28 Oct 27, 2022: Integer Holdings Reports Third Quarter 2022 Results 117

6.29 Oct 19, 2022: Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement 118

6.30 Sep 22, 2022: Insulet to Announce Third Quarter 2022 Financial Results on November 3, 2022 118

6.31 Sep 22, 2022: MicroTech Medical Inc announced interim report for 2022 118

6.32 Sep 07, 2022: Medtronic to appear at September investor conferences 118

6.33 Sep 06, 2022: LifeScan Names Rekha Ramesh Chief Digital and Information Officer 118

6.34 Aug 31, 2022: Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference 119

6.35 Aug 25, 2022: Lilly to Participate in Citi’s 17th Annual BioPharma Conference 119

6.36 Aug 23, 2022: Medtronic reports first quarter fiscal 2023 financial results 119

6.37 Aug 23, 2022: Medtronic Announces Quarterly Earnings Results 122

6.38 Aug 22, 2022: Tandem Diabetes Care Announces Upcoming Conference Presentations 125

7 Appendix 126

7.1 Methodology 126

7.2 About GlobalData 129

7.3 Contact Us 129

7.4 Disclaimer 129

Frequently asked questions

Insulin Pumps Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies thematic reports
Currency USD
$4,000

Can be used by individual purchaser only

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Insulin Pumps Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Insulin Pumps Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies in real time.

  • Access a live Insulin Pumps Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.